These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 7635796)

  • 1. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
    Byhardt RW
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.
    Lee CB; Stinchcombe TE; Rosenman JG; Socinski MA
    Clin Lung Cancer; 2006 Nov; 8(3):195-202. PubMed ID: 17239295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
    Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
    Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
    Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
    Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
    Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
    Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
    Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
    Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
    Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M; Chapman R; Kim JH
    Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
    Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
    Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
    Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation therapy alone in early stage non-small cell lung cancer.
    Zimmermann FB; Bamberg M; Molls M; Jeremic B
    Semin Surg Oncol; 2003; 21(2):91-7. PubMed ID: 14508859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.